Innovation Articles

  1. Strategic Synthesis Of ASGCT And ASCO 2026 6/10/2026

    The spring 2026 conference season made one thing obvious to those of us watching the data: the artisan era of ex vivo cellular manufacturing is finally receding.

  2. 2026 Nucleate Boston Activator Cohort Interview: Michael Cronce — Omni Therapeutics 6/9/2026

    Omni Therapeutics is developing first-in-class nucleotides from a novel immune metabolite, using Nucleate support to advance colorectal cancer programs.

  3. A New De Novo Protein Design Platform For GPCR Drug Discovery 6/9/2026

    Skape Bio and UW created an AI-driven platform to design miniproteins that modulate GPCRs in living cells, opening new paths for biologic drug discovery.

  4. Discovery Dialogues: Winston Haynes, VP, Computational Sciences and Engineering, LabGenius Tx 6/5/2026

    DDO interviewed Winston Haynes, VP, computational sciences and engineering, LabGenius Tx, on their T-cell engagers platform, including its lead candidate LGTX-101, a Nectin-4 CD3 molecule showing strong preclinical efficacy.

  5. Fostering Entrepreneurial Mentorship And Education: A Peek Into Nucleate Boston Activator 2026 Cohort 6/3/2026

    Nucleate Boston’s 2026 Activator shows how mentorship, structure, and community can help promising young scientists become credible biotech founders.

  6. DDW 2026 Signalled The Next Era Of Competitive Landscape In IBD 6/2/2026

    At the DDW 2026 meeting, the IBD landscape was portrayed as increasingly competitive and diversified, with emerging players and novel mechanisms challenging established standards of care.

  7. Why Tolerability Will Drive The Next Wave Of Obesity Treatments 5/29/2026

    For the next generation of obesity medicines, enhancing how patients experience therapy will inform discovery and development efforts and may ultimately determine long-term success.

  8. What Makes An RNA Platform Investable? Lessons From The Last Wave Of Biotech Financing 5/28/2026

    RNA investing has shifted from hype to scalability, forcing companies to prove manufacturability, delivery strength, and platform-wide value.

  9. Synaptic Regeneration And The Future Of Alzheimer's R&D 5/22/2026

    For too long, treating Alzheimer’s disease has been a case of “managed decline.” We need to move beyond slowing disease progression toward achieving tangible functional recovery.

  10. Unfolding Protein & Antibody Discovery At PEGS 2026 5/19/2026

    Our editorial team covers the 2026 Protein & Antibody Engineering Summit (PEGS) in Boston -- A working map of where biologics R&D is headed.